Linezolid
- Generic Name
- Linezolid
- Brand Names
- Zyvox, Zyvoxam
- Drug Type
- Small Molecule
- Chemical Formula
- C16H20FN3O4
- CAS Number
- 165800-03-3
- Unique Ingredient Identifier
- ISQ9I6J12J
- Background
Linezolid is a synthetic antibiotic which is used for the treatment of infections caused by aerobic Gram-positive bacteria. Its effects are bacteriostatic against both enterococci and staphylococci and bactericidal against most isolates of streptococci. Linezolid exerts its antibacterial activity by inhibiting the initiation of bacterial protein synthesis - ...
- Indication
Linezolid is indicated in adults and children for the treatment of infections caused by susceptible Gram-positive bacteria, including nosocomial pneumonia, community-acquired pneumonia, skin and skin structure infections, and vancomycin-resistant Enterococcus faecium infections. Examples of susceptible bacteria include Staphylococcus aureus, Streptococcus pn...
- Associated Conditions
- Community Acquired Pneumonia (CAP) caused by Staphylococcus Aureus Infections, Community acquired pneumonia caused by Susceptible strains of Streptococcus pneumoniae, Complicated Skin and Skin Structure Infection caused by Staphylococcus Aureus Infections, Complicated Skin and Skin Structure Infection caused by Streptococcus Agalactiae Infection, Complicated Skin and Skin Structure Infection caused by Streptococcus Pyogenes Infection, Nosocomial Pneumonia caused by Staphylococcus Aureus Infections, Nosocomial Pneumonia caused by Streptococcus Pneumoniae Infections, Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus Aureus Infections, Uncomplicated Skin and Skin Structure Infections caused by Streptococcus Pyogenes Infection, Vancomycin-resistant Enterococcus faecium infection
- Associated Therapies
- -
Single and Multiple Ascending Dose Pharmacokinetic Study of TR701 in Healthy Adults
- First Posted Date
- 2008-05-05
- Last Posted Date
- 2017-08-31
- Target Recruit Count
- 80
- Registration Number
- NCT00671814
- Locations
- 🇺🇸
Covance Clinical Research Unit, Madison, Wisconsin, United States
TBTC Study 30: Safety and Tolerability of Low Dose Linezolid in MDR TB
- Conditions
- Interventions
- First Posted Date
- 2008-04-22
- Last Posted Date
- 2012-10-02
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 36
- Registration Number
- NCT00664313
- Locations
- 🇿🇦
King George V Hospital, Durban, South Africa
Safety and Efficacy Study of Oxazolidinones to Treat Uncomplicated Skin Infections
- Conditions
- Interventions
- First Posted Date
- 2008-03-31
- Last Posted Date
- 2014-03-27
- Lead Sponsor
- Melinta Therapeutics, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT00646958
- Locations
- 🇺🇸
Jamaica Hospital Medical Center, Jamaica, New York, United States
🇺🇸Mercury Street Medical Group, LLC, Butte, Montana, United States
🇺🇸Healthcare Partners Medical Group, Los Angeles, California, United States
Efficacy and Safety of Ceftaroline Versus Linezolid in Subjects With Complicated Skin and Skin Structure Infections
- Conditions
- Interventions
- First Posted Date
- 2008-03-11
- Last Posted Date
- 2017-03-14
- Lead Sponsor
- Forest Laboratories
- Target Recruit Count
- 150
- Registration Number
- NCT00633152
- Locations
- 🇺🇸
Investigational Site, Toledo, Ohio, United States
Pharmacokinetics of Linezolid in Children With Cystic Fibrosis
- First Posted Date
- 2008-02-28
- Last Posted Date
- 2020-03-27
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 45
- Registration Number
- NCT00625703
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States
Microbiologic Response With Linezolid And Vancomycin In Ventilator-Associated Pneumonia Due To Methicillin Resistant Staphylococcus Aureus
- Conditions
- Interventions
- First Posted Date
- 2007-12-13
- Last Posted Date
- 2010-06-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 149
- Registration Number
- NCT00572559
- Locations
- 🇵🇷
Pfizer Investigational Site, San Juan, Puerto Rico
Oral Antibiotic Treatment at Home Instead of Intravenous Treatment in Hospital for Resistant Gram Positive Infections
- Conditions
- Interventions
- First Posted Date
- 2007-07-13
- Last Posted Date
- 2023-10-26
- Lead Sponsor
- Imperial College London
- Target Recruit Count
- 211
- Registration Number
- NCT00501150
- Locations
- 🇬🇧
Imperial College London, London, United Kingdom
Steady State Serum and Epithelial Lining Fluid (ELF) Antibiotics Concentrations Under Continous Infusion
- Conditions
- First Posted Date
- 2007-02-14
- Last Posted Date
- 2008-06-09
- Lead Sponsor
- University Hospital Tuebingen
- Target Recruit Count
- 40
- Registration Number
- NCT00435305
- Locations
- 🇩🇪
Universitäsklinikum Tübingen, Klinik für Anästhesiologie und Intensivmedizin, Tübingen, Germany
Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, Isoniazid (INH) and Moxifloxacin in HIV Negative Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis
- Conditions
- Interventions
- First Posted Date
- 2006-11-06
- Last Posted Date
- 2018-11-08
- Target Recruit Count
- 70
- Registration Number
- NCT00396084
- Locations
- 🇺🇸
San Francisco General Hospital - Pulmonary and Critical Care Medicine, San Francisco, California, United States
🇧🇷Universidade Federal do Espirito Santo - Duke Hubert-Yeargan Center, Vitória, Espírito Santo, Brazil
Evaluation Of Linezolid Pk Profile In Burns Patients
- Conditions
- First Posted Date
- 2005-11-21
- Last Posted Date
- 2009-07-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 16
- Registration Number
- NCT00255996
- Locations
- 🇫🇷
Pfizer Investigational Site, Paris, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.